Rockwell Medical, Shanghai Fosun Pharmaceutical deal

Rockwell granted Fosun’s Wanbang Biopharmaceutical Co. Ltd. subsidiary exclusive, Chinese commercialization rights to Triferic ferric pyrophosphate citrate and calcitriol. Rockwell is eligible to receive up to $39 million in an upfront payment and milestones, plus ongoing earnings from product sales. Rockwell markets Triferic for the replacement of iron to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease (CKD). ...